Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 5,274 | 746 | 4,468 |
| Samples | 1,857 | 331 | 1,504 |
| Peptides | 1,746 | 276 | 1,498 |
Function
LAMA2 · Laminin subunit alpha 2
Laminin, an extracellular protein, is a major component of the basement membrane. It is thought to mediate the attachment, migration, and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components. It is composed of three subunits, alpha, beta, and gamma, which are bound to each other by disulfide bonds into a cross-shaped molecule. This gene encodes the alpha 2 chain, which constitutes one of the subunits of laminin 2 (merosin) and laminin 4 (s-merosin). Mutations in this gene have been identified as the cause of congenital merosin-deficient muscular dystrophy. Two transcript variants encoding different proteins have been found for this gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000421865 | P24043 | 2,353 | 1,640 |
| ENST00000617695 | A0A087WYF1* | 2,089 | 1,551 |
| ENST00000618192 | A0A087WX80* | 832 | 636 |
Gene Properties
Recurrent Mutations
All 1640 amino-acid changes on canonical ENST00000421865 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in LAMA2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in LAMA2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 10/40 25% | 0/0 0% |
| Chronic Myelogenous Leukemia | 5/25 20% | 0/0 0% |
| Endometrial Carcinoma | 13/42 31% | 73/612 12% |
| Melanoma | 23/210 11% | 224/1899 12% |
| Non-Small Cell Lung Carcinoma | 45/304 15% | 131/1390 9% |
| Squamous Cell Lung Carcinoma | 10/57 18% | 73/810 9% |
| Glioblastoma | 9/98 9% | 0/0 0% |
| Small Cell Lung Carcinoma | 2/9 22% | 52/752 7% |
| Acute Myeloid Leukemia | 6/90 7% | 0/0 0% |
| Other Solid Cancers | 12/94 13% | 94/1515 6% |
| Neuroendocrine Tumour | 28/154 18% | 17/577 3% |
| Colorectal Carcinoma | 42/143 29% | 161/3239 5% |
| Gastric Carcinoma | 5/74 7% | 83/1809 5% |
| Cervical Carcinoma | 3/35 9% | 17/422 4% |
| Bladder Carcinoma | 3/58 5% | 39/956 4% |
| Head and Neck Carcinoma | 7/85 8% | 57/1574 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Plasma Cell Myeloma | 8/44 18% | 5/305 2% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Esophageal Carcinoma | 3/23 13% | 26/769 3% |
| Hodgkins Lymphoma | 1/16 6% | 4/122 3% |
| Ewings Sarcoma | 5/63 8% | 6/262 2% |
| Hepatocellular Carcinoma | 5/46 11% | 71/2210 3% |
| Biliary Tract Carcinoma | 4/54 7% | 25/950 3% |
| Esophageal Squamous Cell Carcinoma | 6/51 12% | 69/2550 3% |
| Ovarian Carcinoma | 3/109 3% | 24/998 2% |
| Non-Cancerous | 3/104 3% | 19/830 2% |
| Other Sarcomas | 2/69 3% | 16/699 2% |
| Breast Carcinoma | 14/144 10% | 65/3264 2% |
Mutation Distribution
Where LAMA2 is mutated · all tissues, split by cell line vs tissue
How many mutations in LAMA2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 5,274 mutations in LAMA2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|